- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07290569
Studie s různými dávkami přípravku ORKA-001 u pacientů se středně těžkou až těžkou plakovou psoriázou (EVERLAST-B)
Multicentrická, randomizovaná, dvojitě zaslepená, placebem kontrolovaná studie zjišťující dávkovací rozmezí přípravku ORKA-001 u účastníků se středně těžkou až těžkou plakovou psoriázou
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
This is a multicenter, randomized, double-blinded, placebo-controlled, dose ranging study designed to identify the optimal induction dosing regimen of ORKA-001 in approximately 160 adult participants with moderate-to-severe plaque psoriasis.
The study will evaluate the efficacy and safety of 3 induction dosing regimens of ORKA-001 compared to placebo and will include 3 maintenance regimens.
The study will consist of 4 periods:
- Screening Period of up to 6 weeks
- Induction Period of up to 28 weeks (Day 1 [Baseline] to Week 28)
- Maintenance Period of up to approximately 72 weeks (Week 28 to Week 100)
- Post-treatment Follow-up Period: Participants will have the option to enter the open-label extension (OLE) study. Participants who opt out of the OLE study and/or withdraw from the study must be followed for 48 weeks after the End of Treatment (EOT)/Early Termination (ET) visit.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
British Columbia
-
Surrey, British Columbia, Kanada, V3R 6A7
- Oruka Therapeutics Investigative Site
-
Surrey, British Columbia, Kanada, V3V 0C6
- Oruka Therapeutics Investigative Site
-
-
New Brunswick
-
Fredericton, New Brunswick, Kanada, E3B 1G9
- Oruka Therapeutics Investigative Site
-
-
Ontario
-
Ajax, Ontario, Kanada, L1S 7K8
- Oruka Therapeutics Investigative Site
-
Markham, Ontario, Kanada, L3P 1X3
- Oruka Therapeutics Investigative Site
-
Peterborough, Ontario, Kanada, K9J 5K2
- Oruka Therapeutics Investigative Site
-
-
Quebec
-
Montreal, Quebec, Kanada, HZX 2V1
- Oruka Therapeutics Investigative Site
-
Québec, Quebec, Kanada, G1V 4X7
- Oruka Therapeutics Investigative Site
-
-
-
-
Baden-Wuerrtemberg
-
Heidelberg, Baden-Wuerrtemberg, Německo, 69120
- Oruka Therapeutics Investigative Site
-
-
Hesse
-
Frankfurt am Main, Hesse, Německo, 60590
- Oruka Therapeutics Investigative Site
-
-
Lower Saxony
-
Bad Bentheim, Lower Saxony, Německo, 48455
- Oruka Therapeutics Investigative Site
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Německo, 24105
- Oruka Therapeutics Investigative Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Spojené státy, 85032
- Oruka Therapeutics Investigative Site
-
-
Arkansas
-
North Little Rock, Arkansas, Spojené státy, 72117
- Oruka Therapeutics Investigative Site
-
-
California
-
Los Angeles, California, Spojené státy, 90045
- Oruka Therapeutics Investigative Site
-
Los Angeles, California, Spojené státy, 90024
- Oruka Therapeutics Investigative Site
-
San Diego, California, Spojené státy, 92123
- Oruka Therapeutics Investigative Site
-
-
Florida
-
Miami, Florida, Spojené státy, 33126
- Oruka Therapeutics Investigative Site
-
-
Illinois
-
Rolling Meadows, Illinois, Spojené státy, 60008
- Oruka Therapeutics Investigative Site
-
-
Indiana
-
Plainfield, Indiana, Spojené státy, 46168
- Oruka Therapeutics Investigative Site
-
-
Maryland
-
Rockville, Maryland, Spojené státy, 20850
- Oruka Therapeutics Investigative Site
-
-
New York
-
Kew Gardens, New York, Spojené státy, 11415
- Oruka Therapeutics Investigative Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Spojené státy, 27516
- Oruka Therapeutics Investigative Site
-
-
Ohio
-
Cleveland, Ohio, Spojené státy, 44106
- Oruka Therapeutics Investigative Site
-
Mason, Ohio, Spojené státy, 45040
- Oruka Therapeutics Investigative Site
-
-
Oregon
-
Portland, Oregon, Spojené státy, 97201
- Oruka Therapeutics Investigative Site
-
Portland, Oregon, Spojené státy, 97210
- Oruka Therapeutics Investigative Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19104
- Oruka Therapeutics Investigative Site
-
-
Texas
-
Frisco, Texas, Spojené státy, 75033
- Oruka Therapeutics Investigative Site
-
Houston, Texas, Spojené státy, 77004
- Oruka Therapeutics Investigative Site
-
Webster, Texas, Spojené státy, 77598
- Oruka Therapeutics Investigative Site
-
-
Virginia
-
Norfolk, Virginia, Spojené státy, 23502
- Oruka Therapeutics Investigative Site
-
-
-
-
Barcelona
-
Badalona, Barcelona, Španělsko, 08916
- Oruka Therapeutics Investigative Site
-
Barcelona, Barcelona, Španělsko, 08041
- Oruka Therapeutics Investigative Site
-
-
Madrid
-
Madrid, Madrid, Španělsko, 28002
- Oruka Therapeutics Investigative Site
-
Madrid, Madrid, Španělsko, 28046
- Oruka Therapeutics Investigative Site
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Participants ≥ 18 years of age
-
Have a diagnosis of plaque psoriasis for > 6 months
-
Have moderate-to-severe chronic plaque psoriasis defined as:
- BSA ≥ 10%, and
- PASI ≥ 12, and
- IGA score of ≥ 3 on a 5-point scale
-
Candidate for systemic therapy or phototherapy
-
Women of childbearing potential must have a negative pregnancy test.
Exclusion Criteria:
- Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis
- Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
- History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence
- A known hypersensitivity to any components of the ORKA-001 drug product
- Women who are breastfeeding or plan to breastfeed during the study
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: (Induction Period - Arm 1) ORKA-001
Participants will receive 37.5 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Experimentální: (Induction Period - Arm 2) ORKA-001
Participants will receive 300 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Experimentální: (Induction Period - Arm 3) ORKA-001
Participants will receive 600 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Komparátor placeba: (Induction Period - Arm 4) Placebo
Participants will receive Placebo per protocol Induction regimen. |
Placebo administered by subcutaneous (SC) injection |
|
Experimentální: (Maintenance Period - Arm 1) ORKA-001
Participants will receive 300 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Experimentální: (Maintenance Period - Arm 2) ORKA-001
Participants will receive 600 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Komparátor placeba: (Maintenance Period - Arm 3) Placebo
Participants will receive Placebo per protocol Maintenance regimen, based on protocol defined response. |
Placebo administered by subcutaneous (SC) injection |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16
Časové okno: Week 16
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 16
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Proportion of Participants Who Achieve an IGA = 0 (Clear) at Week 16
Časové okno: Week 16
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
Proportion of Participants Achieving 90% Reduction in PASI Score at Week 16
Časové okno: Week 16
|
Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 16
|
|
Proportion of Participants Who Achieve an IGA = 0 (Clear) or 1 (Almost Clear) at Week 16
Časové okno: Week 16
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
Proportion of Participants Maintaining 100% Reduction in PASI Score at Week 100
Časové okno: Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Proportion of Participants Maintaining an IGA = 0 (Clear) at Week 100
Časové okno: Week 100
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 100
|
|
Proportion of Participants Maintaining 90% Reduction in PASI Score at Week 100
Časové okno: Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Proportion of Participants Maintaining an IGA = 0 (Clear) or 1 (Almost Clear) at Week 100
Časové okno: Week 100
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 100
|
|
Proportion of Participants Maintaining 75% Reduction in PASI Score at Week 100
Časové okno: Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs)
Časové okno: Day 1 through Week 100
|
Incidence of treatment adverse events, treatment adverse events of special interest, and clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms |
Day 1 through Week 100
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- ORKA-001-114
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .